Revenue growth masks profit collapse; projects ahead of problems

Revenue ₹304.2 Cr (+15.6% YoY accurate), but PAT ₹3.2 Cr (-78.4% YoY)

33% vs 30% confirmed; EBITDA ₹25 Cr vs ₹10 Cr (+150%)

Pricing pressure persists (cefixime 'maximum stress'), volumes improving but margins compressed

No contradictions; equipment rerouted through Italy but timelines intact per Q&A

Plausible given 10-12 year stability, but Pen G precedent (dumping happened) suggests risk is real

Prior FY27 expected 10-15% growth; Q1 delivered +76% revenue but PAT -78%. Management now declining FY27 guidance, saying 'not prudent,' signaling caution on sustaining margin recovery

Gross margin 30% (Q1 FY26) → 33% (Q1 FY27), EBITDA ₹10→25 Cr; merger integration projects expected to deliver 'initial benefits' next FY

No timeline slip, but management candid: fermentation is 'unpredictable,' Aurobindo took longer, targeting 12-month ramp but 'might be longer'

Regulated product demand cyclical; Q1 was mediocre, H2 typically better (winter). Hopes next 2-3 quarters improve, but no guarantee; depends on demand cycle.

80-100% by end of year one, initially slow then progressive. Long-term: 80% in-house, 20% third-party. Initially all in-house for GMP approvals.

Concentrated 3-4 suppliers (Sinopharm Weiqida, Zhuhai United, Yili, Livzon). Pricing stable $60 last 10-12 years. Chinese now profit-focused (unlike 20 years ago); unlikely drastic cuts.

Initially CMO in China (long-term agreement with Allecra). We'll register from our cefiderocol site (FY28) and partially supply thereafter.

GCLE procurement driven by product demand. FY26 saw 15-20% volume decline; values fluctuate. No strategic shift; 100% sourced from Otsuka.

Not prudent to give guidance at this time. Hope for better Q-o-Q in H2, but no specific target.

₹750 Cr for 7-ACA, USD 20-25 million for cefiderocol. Most capex will be spent completing these projects in FY27.

Chose Jammu for cost advantage (GST, cheap power, water, waste steam). Pen G comparison: Chinese dumped after PLI but prices rebounded to 2019 levels. 7-ACA stable, no cartel like Pen G. Chinese now profit-focused.

Comprehensive agreement. They handhold, support production, continue strain development, provide better strains, help improve technology. They have incentive to support.

Guiding 12 months but might be longer (Aurobindo precedent). 20x pilot scale-up done; 800x to Jammu unpredictable. First batch Feb-Mar '27, then stabilization.

Long-term guidance $1.1-2B lifetime (unchanged). Not guiding Advanz-specific revenue. Partners believe it's viable; actual monetization is long-term, unpredictable.

Agreement just signed. Registration dossier + launch ~1.5-2 years.

Cefepime-Enmetazobactam got waiver due to antimicrobial resistance + unmet need. Using that precedent to engage stakeholders. Result only known after application.

Cefixime (Pen G + GCLE derived) under pressure in ROW (high volumes). Strategy: diversify, sole-source niche products, backward integrate (7-ACA), move to formulations. Competitors focus volumes; we focus value.

Yes, plan to supply non-sterile to Aurobindo and others. Better model than competing with own sterile (approval delays). Collaborate with 4 large sterile manufacturers.

Customers taking product for their development. Validation batches planned this year or early next, then 6 months to US filing. Europe launch under progress.

Q1 EBITDA loss ~₹50 lakh (much better than prior quarter). AMS revenue ₹5 Cr (Orblicef + brands). Building strategic platform; losses reducing significantly.

Guidance 2030. Generic molecules via cefiderocol facility (validation, FDA approval, filing—years). Newer molecules via CMO, faster launch, nothing before 2028. Annual updates only.

Q1 sales ₹21 Cr (or ₹20-25 Cr per quarter typically). Working on couple of molecules; scaling and backward integrating. Will it be 25% in 3-4 years? No.

Prior FY-2026 calls indicated 10-15% growth for FY27. Manish Dhanuka: 'not prudent to give you any number at this time.' Signals caution.

Regulated market demand cyclical; Q1 'mediocre', H2 historically stronger (winter season). But 'hope' is not guarantee; pricing pressure persists.

Commercial batch March 2027; ramp 80-100% over 12 months. Capex ₹750 Cr sunk; first meaningful revenue FY28.

Cephalosporin API 'low-margin business going forward' per management. Cefixime under 'maximum stress'. Gross margin recovery offset by depreciation/interest from capex.

Strategy to move up value chain (API→formulations, Exblifep, cefiderocol). 7-ACA will reduce Pen G/GCLE dependency. But execution risk: ramp complexity, pricing unknown.

Equipment rerouting delays noted but overall timeline intact (March 2027 commercial batch)

Facility ready Dec 2026; product approval 6-9 months thereafter (Q3 FY28)

Both mega-projects completing. Limited maintenance capex thereafter unless new projects announced.

Cefixime under 'maximum stress' in ROW; Pen G saw price crash post-PLI despite cartel setup. 7-ACA stable but Chinese competitors could undercut if incentivized.

Fermentation is 'unpredictable'; 20x pilot scale-up done, 800x to Jammu untested. Aurobindo took longer than expected. First batch Feb-Mar '27 will reveal quality/yield.

Q1 PAT ₹3.2 Cr (1.1% NPM) despite ₹304 Cr revenue and ₹25 Cr EBITDA. Depreciation/interest from ₹750 Cr capex + merger integration costs eating profit. Operating leverage not yet visible.

Cefiderocol clinical trial waiver hoped for but not assured. DCGI SEC committee decision unpredictable. Precedent (Cefepime-Enmetazobactam) helped, but no guarantee for cefiderocol.

Q1 regulated market demand 'mediocre'; H2 expected stronger but uncertain. Middle East launch affected by 'regional conflict'. Exblifep volume growth (300%→50% QoQ) decelerating.